Göran Wessman resigns from the Board – joins the Nomination Committee now appointed in Vicore Pharma Holding

Mölndal, October 22, 2018 - Due to personal reasons, Göran Wessman has chosen to resign from the Board of Directors of Vicore Pharma Holding AB (publ) and will instead join the nomination committee of Vicore Pharma Holding AB (publ) as representative of Protem Wessman AB.

Göran Wessman, board member of Vicore Pharma Holding AB (publ) since 2005, has notified the board of his decision to resign due to health reasons and, in connection with this, announced that he wishes to become a member of the company's nomination committee. As a representative of one of the company's three largest owners - Protem Wessman AB - Göran Wessman has the right to appoint one of the members of the Nomination Committee.

”I am very confident in Vicore’s future development and will follow the company with great engagement as member of the Nomination Committee among others” says Göran Wessman in a comment.

The Board has seven remaining members after Göran Wessman’s departure. As this number is sufficient according to the Articles of Association limits for the number of Board members, the Board has decided not to fill the vacancy during the current term of office, which is until the 2019 Annual General Meeting.

"Göran Wessman has been on the board for thirteen years and through his company, Protem Wessman AB, one of Vicore’s largest shareholders. I would like to thank him for his great commitment and genuine interest in Vicore's development. We are pleased that Göran will now be included in the company's Nomination Committee," said Leif Darner, chairman of Vicore Pharma.

Vicore Pharma Holding's Nomination Committee for the Annual General Meeting in 2019 has been formed in accordance with the decision of the Extraordinary Meeting of August 13, 2018. The three largest shareholders as of September 30, 2018 have each been offered to appoint one representative to the Nomination Committee.

The Nomination Committee consists of Staffan Lindstrand appointed by HealthCap VII L.P., Göran Wessman as representative of Protem Wessman AB and Evert Carlsson as representative of Swedbank Robur. Vicore Pharma’s chairman, Leif Darner, is also a member and acts as the convener of the Nomination Committee.

The Nomination Committee's task is to prepare and submit proposals for the number of Board members to be elected by the AGM, election of the chairman and other members of the Board, Board fees and possible remuneration for committee work, election of chairman of the AGM, election of auditors (if applicable) and auditor's fees and proposed rules for the appointment of the Nomination Committee for the 2019 Annual General Meeting.

The Annual General Meeting of Vicore Pharma Holding AB (publ) will take place on May 15, 2019 at the company's premises at Astra Zeneca in Mölndal. Shareholders who wish to submit comments or proposals to the Nomination Committee may do this by 15 March 2019 by email to info@vicorepharma.com or by letter to Vicore Pharma Holding AB (publ), c / o BioVentureHub, Pepparedsleden 1, 431 83 Mölndal. The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting and on the company's website.

For further information, please contact:

Leif Darner, chairman of the board, tel: +46 705 79 04 62, leif.darner@vicorepharma.com

This information is information that Vicore Pharma Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 12:00 CET on October 22, 2018.

About Vicore Pharma Holding AB (publ)
Vicore Pharma AB is focused on the development of drugs for the treatment of interstitial lung diseases. The company’s two major development programs, VP01 (C21) and VP02 (IMiD), act through the AT2 receptor and is an immunomodulatory drug substance class being developed for local treatment, respectively. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. VP02 has in earlier experiments shown an effect in e.g. idiopathic pulmonary fibrosis with another administration form which, however, has limited its continued development. VP02 is being developed for local treatment in order to e.g. overcome such shortcomings. The company is based in AstraZeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com 

About Us

Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com

Subscribe

Documents & Links